Biosimilar User Fees Would Be Same As BLAs, Only Earlier
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's proposed biosimilar product development fee would be charged upon IND submission, but subtracted from marketing application fee.
You may also be interested in...
Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
Tentative agreement closely resembles FDA's original proposal.
Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
Tentative agreement closely resembles FDA's original proposal.
Biosimilar Product Development Meetings With FDA To Be Flexible Under User Fee Program
Agency says pre-marketing application meetings will not be mandatory; program independence issue also appears resolved.